Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 250 movers: Asos in fashion on bid talk; Dr Martens out of step on Barclays downgrade
(Sharecast News) - Asos is reportedly on bid alert after the online fashion retailer received a £1bn approach from a Turkish company backed by Chinese giant Alibaba.
The Times cited city sources as saying that Asos received an approach from Turkish online retailer Trendyol in late December. The mooted deal would have valued Asos at between £10 and £12 a share.
The retailer's shares closed at 350p on Friday after it was ejected from the FTSE 250. Leading credit insurers have also recently withdrawn or reduced cover for the retailer's suppliers, a move that could further squeeze its cash flow.
It was understood that Trendyol has been working with advisers from Morgan Stanley. Neither party is under pressure to confirm discussions because there are no live talks. Asos and Trendyol declined to comment to The Times.
Last month, Asos was forced to shore up its finances by raising £75m from investors via a share placing. It also entered into £275m of new debt facilities at an average interest rate of 11%. The capital raise was supported by Anders Holch Povlsen, the Danish billionaire who is Asos's largest shareholder with a 26% stake.
Billionaire retail tycoon Mike Ashley has built a 7.4% stake in Asos.
City sources told The Times that Trendyol also approached Povlsen about the potential Asos deal to see whether he would be interested in participating. Lise Kaae, chief executive of Heartland, Povlsen's investment vehicle, told The Times: "Regarding rumours and speculations, we adhere to our practice of not commenting."
Leading credit insurer Allianz Trade withdrew cover entirely for Asos suppliers last week, citing adverse economic conditions and the retailer's finances. Atradius, another leading insurer, is also understood to have reduced cover. The removal of credit insurance, which protects suppliers from the risk of a retailer being unable to pay its debts, can spur suppliers to demand payment upfront.
An Asos spokeswoman told The Times: "Credit insurance cover has been tightening across the industry. We have not seen any adverse impact on trading relationships with suppliers due to changes to cover."
At 0940 BST, the shares were up 12.9% at 395.60p.
Russ Mould, investment director at AJ Bell, said the report shows that "someone was prepared to look through near-term problems and focus on the potential to revive the company's fortunes and put its brand back at the top of the fast fashion segment".
He continued: "Given that it has been six months since Turkey's Trendyol reportedly made the approach, one can assume that talks are not ongoing, otherwise we would have heard something from Asos by now.
"However, some shareholders may be frustrated that Asos didn't publicly disclose the approach, assuming the reports are correct. With the shares having slumped to £3.50 last week, there may be a group of investors who would be eager to accept a bid potentially three times that level.
"The weekend reports about the bid talks may force Asos to issue a statement and one would have thought CEO Jose Antonio Ramos Calamonte's phone won't have stopped ringing since the weekend.
"Takeover interest often emerges when a broken company lays out a recovery plan and there are early signs it is working. Those green shoots can give a suitor confidence it is worth making a bid now rather than waiting for the company to be repaired and then having to pay a much higher price when the risks are lower.
"Asos reported a significant improvement in profitability at the start of the year, perhaps explaining why it may not have been prepared to entertain takeover talks. It has since raised £75 million to help fund its turnaround and strengthen its finances.
"However, half-year results in May were disappointing with losses widening and an ongoing struggle with day-to-day trading. It has suffered from holding too much inventory and having to slash prices to clear this stock. That goes to show its recovery plan is still in the very early stages and that it remains vulnerable to further takeover interest while the share price remains in the doldrums."
Addiction treatment-focused pharmaceuticals company Indivior announced on Monday that its subsidiary Indivior Inc has successfully reached an agreement to resolve the claims brought against it by the attorneys general of 41 US states and the District of Columbia.
The claims were part of the suboxone antitrust multidistrict litigation (MDL).
It said the agreement, once entered by the United States District Court for the Eastern District of Pennsylvania, would mark a comprehensive resolution of the states' claims against the company in the MDL.
Under the deal, Indivior Inc agreed to pay $102.5m to the claimants, aligning with its initial provision of $290m set aside for the overall MDL.
The payment was expected to be made in June, and would be funded from the company's existing cash reserves.
Additionally, the claimants had agreed to release all claims related to the MDL, and in return, Indivior said it had committed to specific notification provisions and restrictions similar to those outlined in the 10-year stipulated order entered into with the Federal Trade Commission (FTC) in November 2020.
Those provisions and restrictions would run concurrently with the FTC stipulated order.
"Indivior is focused on helping those who suffer from substance use disorders," said chief executive officer Mark Crossley.
"We take our role as a responsible steward of medications for addiction and rescue extremely seriously.
"Resolving these legacy matters at the right value allows us to further this mission for patients."
Ithaca Energy gained on higher oil prices as Saudi Arabia and other OPEC producers pledged to cut production.
Dr Martens fell after Barclays downgraded earnings for 2024/25 after last week's profits warning and poor results.
FTSE 250 - Risers
Indivior (INDV) 1,589.00p 7.73% ASOS (ASC) 377.40p 7.71% Ithaca Energy (ITH) 149.00p 5.23% Sirius Real Estate Ltd. (SRE) 88.60p 4.42% Elementis (ELM) 113.20p 2.91% Petershill Partners (PHLL) 156.40p 2.76% Morgan Advanced Materials (MGAM) 297.00p 2.24% PureTech Health (PRTC) 235.50p 2.17% Baltic Classifieds Group (BCG) 164.40p 2.11% JPMorgan Japanese Inv Trust (JFJ) 509.00p 2.11%
FTSE 250 - Fallers
Ferrexpo (FXPO) 95.95p -4.24% Dr. Martens (DOCS) 134.70p -3.65% AJ Bell (AJB) 318.20p -3.58% Genus (GNS) 2,468.00p -2.99% Just Group (JUST) 83.90p -2.89% Bakkavor Group (BAKK) 92.00p -2.75% Watches of Switzerland Group (WOSG) 660.50p -2.65% Molten Ventures (GROW) 303.80p -2.57% Aston Martin Lagonda Global Holdings (AML) 269.00p -2.47% Rathbones Group (RAT) 1,958.00p -2.34%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.